High rate of seroeligibility among MYBPC3-associated hypertrophic cardiomyopathy patients for TN-201, an adeno-associated virus serotype 9 MYBPC3 gene therapy. This evidence concerns the gene MYBPC3 and hypertrophic cardiomyopathy.